Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.

Related Keywords

Brian Goff , Agios Pharmaceuticals , Drug Administration , Royalty Pharma , Chief Executive Brian Goff ,